No products in the cart.
A fusion event involving CCND1 and IGH has been widely reported in many hematologic tumors such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, multiple myeloma, and plasma cell leukemia1. It is often thought of as a signpost marker for MCL,the frequency of t(11;14) for this type of lymphoma has been reported as 50-70%2,3.
FOR DISTRIBUTION OUTSIDE THE UNITED STATES ONLY
|Download OUS Datasheet|
IVD is NOT for Sale in the United States but may be available in certain countries outside of the United States, please contact your local distributor for more information.
1. Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case. Ishigaki T, Sasaki K, Watanabe K, Nakamura N, Toyota S, Kobayashi H, Tohda S. Cancer Genet Cytogenet. 2010 Aug;201(1):62-5.
2. The ultrastructure of mantle cell lymphoma and other B-cell disorders with translocation t(11;14)(q13;q32). Resnitzky P, Matutes E, Hedges M, Morilla R, Brito-Babapulle V, Khokhar T, Catovsky D. British journal of haematology. 1996 ; 94 (2) : 352-361.
3. Insertion of the CCND1 gene into the IgH locus in a case of leukaemic small cell mantle lymphoma with normal chromosomes 11 and 14. A Aventín, J Nomdedéu, J Briones, I Espinosa, R Bordes, J Sierra. J Clin Pathol 2003;56:798–800
4. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.